Sameer Rastogi, Additional Professor of Sarcoma and GIST Medical Oncology Clinic at AIIMS, New Delhi, shared a post on X:

“We are pleased to share the preliminary results of SORASTOP, which investigates whether sorafenib can be discontinued in individuals with desmoid tumors who are responding to treatment. Good early results.”

Title: Clinico-radiological outcomes of desmoid type-fibromatosis after discontinuing the sorafenib treatment in responders – early results from the SORASTOP study

Authors: Bharath B Gangadharaiah, Ghazal Tansir, Sameer Rastogi, Simran Kaur, Vikas Garg, Ekta Dhamija, Adarsh Barwad, Shivanand Gamanagatti, Sandeep Bhoriwal and Maroof A Khan

Read Full Article on ecancer.

SORASTOP

Further Reading:

Sorafenib (Nexavar): Uses in Cancer, Side Effects, Dosage, Expectations, and More

Sorafenib (Nexavar): What patients need to know?

Sameer Rastogi Shared Early Results from SORASTOP Trial on Discontinuing Sorafenib in Desmoid Tumors

“We are pleased to share the preliminary results of SORASTOP, which investigates whether sorafenib can be discontinued in individuals with desmoid tumors who are responding to treatment. Good early results.”